Frontlight ResearchEarly access
TerminatedNo phase
Zemedy Application for Irritable Bowel Syndrome
Key facts
- Who runs it
- Stanford University
- Where
- Redwood City, United StatesSee the site
- Trial code
- Status
- Terminated
- People taking part
- 21 people enrolled
- Started
- 15 Oct 2021
- Ended
- 8 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Use of Zemedy Application
- Record updated
- 28 May 2025
- Why it stopped
- Loss of funding
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Male and female patients >=18 years old
- Meet Rome IV criteria for IBS for at least 6 months. No restrictions on type of IBS
- English proficiency (in order to understand use of the application
- Patient must be on a stable regimen for IBS for at least 30 days
- Patients must own a smartphone (iOS or Android) in order to participate in the CBT application
Who cannot take part
- Patient already undergoing cognitive behavioral therapy
- Active gastrointestinal disease such as Crohn's disease, ulcerative colitis, history of complete colon resection, acute infection, or any disease that precludes participation in CBT application
- Psychiatric hospitalization within 10 years
- Current or past diagnosis of a major mental illness such as schizophrenia, bipolar disorder, personality disorder or substance abuse
- Laboratory or imaging evidence of an alternative explanation of patient's symptoms
- Active (within the past 3 months) suicidal ideation
- Prisoners or other detained individuals
- Adults unable to consent
- Pregnant people
Where in United States
- Stanford University School of MedicineRedwood City, United States
About the trial
What the trial wants to find out
The purpose of the study is investigate the effectiveness of Zemedy, a mobile application that enables the digital delivery of a CBT program to people with IBS.
The 2 groups in the trial
- Control Group (TAU only)No study treatment, for comparison
Treatment as Usual (TAU) for IBS patients are tailored to each individual's needs and may involve treatment such as: dietary modification, exercise, medication, and anti-diarrheal therapy.
- Experimental (TAU plus CBT)Treatment being tested
Subjects who are in the Experimental Group will receive 8 weeks of CBT from the Zemedy mobile application in addition to their treatment as usual (TAU).
Treatment: Use of Zemedy Application
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Zemedy - Evaluation of Zemedy, a Cognitive Behavioral Therapy-based Digital Therapeutic Application for the Treatment of Irritable Bowel Syndrome
- Record updated
- 28 May 2025